Results 91 to 100 of about 183,958 (171)

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer. [PDF]

Clin Cancer Res
Casak SJ, Zhang Y, Song C, Mishra-Kalyani PS, Tang S, Auth D, de Claro RA, Pazdur R, Lemery SJ.   +8 more
europepmc   +1 more source

Pembrolizumab-Responsive Cerebellar PML in Untreated Sarcoidosis: A Case Report. [PDF]

Cerebellum
Jack-Kee E, Hoyle N, Hadjivassiliou M.
europepmc   +1 more source

Near-complete pathologic resolution of untreated papillary thyroid cancer after pembrolizumab-induced thyroiditis. [PDF]

JCEM Case Rep
Locke M, Sternbach S, Seetharamu N, Taneja C.   +3 more
europepmc   +1 more source

Complete Response to Pembrolizumab After Progression on Avelumab Maintenance in Metastatic Urothelial Carcinoma. [PDF]

IJU Case Rep
Ito F, Kobayashi K, Hayashi G, Kamijo S, Fujita T.   +4 more
europepmc   +1 more source

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775. [PDF]

J Immunother Cancer
Makker V, Colombo N, Casado A, Santin AD, Colomba E, Miller DS, Fujiwara K, Pignata S, Yonemori K, Kim YM, Baron-Hay S, Ray-Coquard I, Shapira-Frommer R, Kristeleit R, Nishio S, Suzuki S, Guerra Alía EM, Sanli UA, Selle F, Shikama A, Martínez Rodríguez JL, Arik Z, Arican A, Sebastianelli A, Yu Z, McKenzie J, Kruger S, Meng R, Okpara CE, Lorusso D.   +29 more
europepmc   +1 more source

Timing matters: concurrent <i>vs.</i> sequential immunotherapy in combination with chemoradiation in head and neck cancer. [PDF]

Transl Cancer Res
Bachmann LM, El-Gamal D, Wise-Draper TM.
europepmc   +1 more source

Revisiting the Immune Frontier in Soft Tissue Sarcomas. [PDF]

Curr Oncol Rep
Bilani N, Al Akoum N, Al-Marayaty R, Orlando S, Alexiev B, de Viveiros PH, Pollack SM.   +6 more
europepmc   +1 more source

Basal cell carcinoma: Management of advanced or metastatic cancer with checkpoint inhibitors and concurrent paradoxical development of new superficial tumors. [PDF]

, 2020
Cohen, Philip R, Kurzrock, Razelle
core   +1 more source

Thrombotic thrombocytopenic purpura as a complication of pembrolizumab: a case report and literature Review. [PDF]

Ann Hematol
Palega G, Al-Rikabi IA, Kopaczek-Styczen M, Karlström C.   +3 more
europepmc   +1 more source

Pembrolizumab in programmed death ligand 1-positive endometrial cancer [PDF]

, 2017
BENEDETTI PANICI, Pierluigi, Tomao, Federica, Tomao, Silverio   +2 more
core   +1 more source